ATE267179T1 - Substituierte diamino-1,3,5-triazinderivate - Google Patents

Substituierte diamino-1,3,5-triazinderivate

Info

Publication number
ATE267179T1
ATE267179T1 AT97202917T AT97202917T ATE267179T1 AT E267179 T1 ATE267179 T1 AT E267179T1 AT 97202917 T AT97202917 T AT 97202917T AT 97202917 T AT97202917 T AT 97202917T AT E267179 T1 ATE267179 T1 AT E267179T1
Authority
AT
Austria
Prior art keywords
triazine derivatives
substituted diamino
diamino
substituted
triazine
Prior art date
Application number
AT97202917T
Other languages
English (en)
Inventor
Michael Joseph Janssen R Kukla
Spring House Roads
Donald W Janssen Res Ludovici
House Spring
Paul Adriaan Jan Janssen
Jan Heeres
Henri Emiel Lodewijk Moereels
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE267179T1 publication Critical patent/ATE267179T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT97202917T 1996-10-01 1997-09-24 Substituierte diamino-1,3,5-triazinderivate ATE267179T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2726096P 1996-10-01 1996-10-01

Publications (1)

Publication Number Publication Date
ATE267179T1 true ATE267179T1 (de) 2004-06-15

Family

ID=21836641

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97202917T ATE267179T1 (de) 1996-10-01 1997-09-24 Substituierte diamino-1,3,5-triazinderivate

Country Status (33)

Country Link
US (4) US6380194B1 (de)
EP (1) EP0834507B1 (de)
JP (1) JP4127882B2 (de)
KR (1) KR100478846B1 (de)
CN (1) CN1083438C (de)
AP (1) AP914A (de)
AR (1) AR008864A1 (de)
AT (1) ATE267179T1 (de)
AU (1) AU740809B2 (de)
BR (1) BR9704937A (de)
CA (1) CA2216486A1 (de)
CZ (1) CZ297333B6 (de)
DE (1) DE69729153T2 (de)
DK (1) DK0834507T3 (de)
EE (1) EE03826B1 (de)
ES (1) ES2221679T3 (de)
HR (1) HRP970526B1 (de)
HU (1) HU225270B1 (de)
ID (1) ID19599A (de)
IL (1) IL121849A (de)
MY (1) MY123803A (de)
NO (1) NO311614B1 (de)
NZ (1) NZ328854A (de)
OA (1) OA10620A (de)
PL (1) PL190155B1 (de)
PT (1) PT834507E (de)
RU (1) RU2186774C2 (de)
SG (1) SG53075A1 (de)
SI (1) SI0834507T1 (de)
SK (1) SK285241B6 (de)
TR (1) TR199701070A2 (de)
TW (1) TW411335B (de)
ZA (1) ZA978766B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
JP3635238B2 (ja) 1998-11-10 2005-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖの複製を阻害するピリミジン類
AP1636A (en) * 1998-11-10 2006-07-17 Janssen Pharmaceutica Nv 2.4-disubstituted triazine derivatives.
DE60025837T2 (de) * 1999-09-24 2006-11-02 Janssen Pharmaceutica N.V. Antivirale feste dispersionen
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
ATE449764T1 (de) * 1999-12-28 2009-12-15 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US7276510B2 (en) 2000-05-08 2007-10-02 Janssen Pharmaceutica, Inc. HIV replication inhibitors
US7034019B2 (en) 2000-05-08 2006-04-25 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
DE60235470D1 (de) * 2001-06-26 2010-04-08 Pharmacopeia Inc N-heterocyclische inhibitoren der expression von tnf-alpha
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
CN1582277A (zh) 2001-11-01 2005-02-16 詹森药业有限公司 用作糖原合酶激酶3β抑制剂的酰胺衍生物
MXPA04004178A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta.
WO2003096982A2 (en) * 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003097806A2 (en) 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CN102503903A (zh) * 2003-02-07 2012-06-20 詹森药业有限公司 抑制hiv的1,2,4-三嗪
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
WO2005003103A2 (en) * 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
RU2401833C2 (ru) 2004-08-10 2010-10-20 Янссен Фармацевтика Н.В. Производные 1, 2, 4-триазин-6-она, ингибирующие вич
CA2578995A1 (en) * 2004-09-03 2006-03-09 Prometic Biosciences Inc. 2,4,6-triamino-s-triazine-based compounds which bind to the tail (fc) portion of immunoglobulins and their use
CA2577467C (en) 2004-09-30 2013-05-28 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-heterocyclyl pyrimidines
US7531548B2 (en) 2004-09-30 2009-05-12 Tibotec Pharmaceuticals Ltd HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines
RU2410379C2 (ru) 2004-09-30 2011-01-27 Тиботек Фармасьютикалз Лтд. 5-замещенные пиримидины, ингибирующие вич
US8153640B2 (en) 2004-10-29 2012-04-10 Tibotec Pharmaceuticals Ltd. HIV inhibiting bicyclic pyrimdine derivatives
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US20060281712A1 (en) 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
EP2004632B1 (de) 2006-03-30 2014-03-12 Janssen R&D Ireland Hiv-inhibierende 5-amido-substituierte pyrimidine
US9006243B2 (en) 2006-12-29 2015-04-14 Janssen R&D Ireland HIV inhibiting 6-substituted pyrimidines
CN106045965A (zh) * 2006-12-29 2016-10-26 爱尔兰詹森科学公司 抑制hiv的5,6‑取代的嘧啶类化合物
EP2152676B1 (de) * 2007-04-30 2013-04-03 ProMetic BioSciences Inc. Triazinderivate, zusammensetzungen, die solche derivate enthalten, und verfahren zur behandlung von krebs und autoimmunkrankheiten unter verwendung solcher derivate
EP2268635B1 (de) 2008-04-21 2015-06-10 Taigen Biotechnology Co., Ltd. Heterocyclische verbindungen
TW201021855A (en) 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
US9058223B2 (en) * 2011-04-22 2015-06-16 Microsoft Technology Licensing Llc Parallel entropy encoding on GPU
CA2888413C (en) * 2012-10-24 2021-11-16 Basf Se Herbicidal azines
US10941122B2 (en) * 2014-04-11 2021-03-09 Basf Se Diaminotriazine derivatives as herbicides
WO2016059647A2 (en) * 2014-10-13 2016-04-21 SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1
CN105837525B (zh) * 2016-03-25 2019-05-28 浙江工业大学 2,4-二胺-1,3,5-三嗪类化合物及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE226474C (de)
US2309663A (en) * 1943-01-26 Process fok preparing substituted
US2817814A (en) 1953-08-13 1957-12-24 Gen Electric Corona detection probe
US2817614A (en) * 1953-10-26 1957-12-24 Monsanto Chemicals Internally plasticized melamine resins and laminates made therewith
GB771327A (en) 1953-10-26 1957-03-27 Monsanto Chemicals Production of heat hardenable melamine-formaldehyde condensation products
JPS4927592B1 (de) 1970-05-13 1974-07-18
GB1390235A (en) 1971-08-07 1975-04-09 Kakenyaku Kako Kk 2-amino-4,6substituted-s triazines and methods for their preparation
DE3724379A1 (de) * 1987-07-23 1989-02-02 Bayer Ag Verfahren zur herstellung feinteiliger magnetischer hexaferritpigmente
CA2027562C (en) * 1989-02-20 1994-05-10 Masahiro Nishii Triazine derivative and a herbicide comprising the same as an effective ingredient
US5536722A (en) * 1991-11-12 1996-07-16 Pfizer Inc. Triazine derivatives for enhancing antitumor activity
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
JP3398152B2 (ja) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater

Also Published As

Publication number Publication date
BR9704937A (pt) 2000-06-06
SK285241B6 (sk) 2006-09-07
SI0834507T1 (en) 2004-10-31
NO974368D0 (no) 1997-09-22
PL322369A1 (en) 1998-04-14
HUP9701596A3 (en) 2000-04-28
HUP9701596A2 (hu) 1999-06-28
ID19599A (id) 1998-07-23
CZ297333B6 (cs) 2006-11-15
TW411335B (en) 2000-11-11
AR008864A1 (es) 2000-02-23
CZ299397A3 (cs) 1998-11-11
NZ328854A (en) 2000-10-27
DK0834507T3 (da) 2004-09-06
OA10620A (en) 2002-09-03
KR19980032428A (ko) 1998-07-25
AU740809B2 (en) 2001-11-15
MY123803A (en) 2006-06-30
US6380194B1 (en) 2002-04-30
US6962916B2 (en) 2005-11-08
AU3926697A (en) 1998-04-09
EE9700253A (et) 1998-04-15
AP914A (en) 2000-12-18
SK131997A3 (en) 1999-06-11
CN1083438C (zh) 2002-04-24
US6858609B2 (en) 2005-02-22
IL121849A (en) 2001-08-26
DE69729153D1 (de) 2004-06-24
SG53075A1 (en) 1998-09-28
US20060189614A1 (en) 2006-08-24
HRP970526B1 (en) 2002-10-31
EE03826B1 (et) 2002-08-15
TR199701070A2 (xx) 1998-04-21
HU9701596D0 (en) 1997-11-28
EP0834507B1 (de) 2004-05-19
HK1009676A1 (en) 1999-06-04
DE69729153T2 (de) 2005-01-27
KR100478846B1 (ko) 2006-06-13
PT834507E (pt) 2004-10-29
IL121849A0 (en) 1998-02-22
NO974368L (no) 1998-04-02
ES2221679T3 (es) 2005-01-01
HU225270B1 (en) 2006-08-28
US20030199473A1 (en) 2003-10-23
US7449575B2 (en) 2008-11-11
PL190155B1 (pl) 2005-11-30
ZA978766B (en) 1999-03-30
US20020147181A1 (en) 2002-10-10
EP0834507A1 (de) 1998-04-08
JPH10114759A (ja) 1998-05-06
HRP970526A2 (en) 1998-10-31
NO311614B1 (no) 2001-12-17
CA2216486A1 (en) 1998-04-01
JP4127882B2 (ja) 2008-07-30
CN1180698A (zh) 1998-05-06
RU2186774C2 (ru) 2002-08-10
MX9707511A (es) 1998-06-30
AP9701109A0 (en) 1997-10-31

Similar Documents

Publication Publication Date Title
DE69729153D1 (de) Substituierte Diamino-1,3,5-Triazinderivate
ATE264327T1 (de) Substituierte 6,6-heterobicyclische derivate
ATE340176T1 (de) Substituierte 6,5-heterobicyclische-derivate
NL1001381C2 (nl) Bis-resorcinyltriazinen.
DE69809755D1 (de) Substituierte 1,2,3,4-tetrahydronaphthalin derivate
FI923314A7 (fi) Substituoidut syklopropyyliamino-1,3,5-triatsiinit
ATE231847T1 (de) Substituierte 1,2,3,4- tetrahydronaphthalinderivate
BR9611570A (pt) Derivados de triazina
TR199501528A1 (tr) Pirol türevleri.
ATE227282T1 (de) 2,4-diaminopyrimidin-derivate
DK0922050T3 (da) 3-Descladinose-2,3-anhydroerythromycin-derivater
EP0668529A3 (de) Triazin-Polymere.
NL1005675A1 (nl) Polytriazinederivaten-bevattende polyalkylpiperidinyloxy- of polyalkylpiperidinylaminogroepen.
PT1129079E (pt) Derivados de triazina 2,4-dissubstituidos
ATE220674T1 (de) 12h-dibenzo(d,g)(1,3)dioxocin derivate
DE69722064D1 (de) 1,25-Dihydroxy-16,22,23-trisdehydro-Cholecalciferol-Derivate
DE69328495D1 (de) 2,3-Dihydrobenzofuran Derivate
LV10616A (lv) Aizvietoti ciklopropilamino-1,3,5-triazini

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0834507

Country of ref document: EP

REN Ceased due to non-payment of the annual fee